Introduction
expressed and associates with the b and c chains to form an IL-2abc complex, which in turn binds IL-2 Although life-long administration of a multi-drug regiwith high affinity ( Kd=10−11 M ). The interaction of men of aspecific small-molecular immunosuppressants IL-2 with this receptor results in a rapid proliferation is most frequently used to prevent rejection of the of the antigen-activated T cells (clonal expansion) leadtransplanted organ, the administration of anti-T cell ing to effector T cells with helper, suppressor or cytoantibodies in the immediate post-transplant period toxic abilities. Depending on the epitope, some anti-(induction therapy) as prophylaxis against rejection or IL-2Ra mAbs block the association of the a-chain with as anti-rejection therapy is still advocated to improve bc complex and the binding of IL-2 with its highlong-term allograft outcome. However, older polyaffinity receptor. Hence, the duration and magnitude clonal (ALS-ATG) and monoclonal (OKT 3 ) antiof this antigen-specific immune response is suppressed T cell antibodies are associated with different sideby blocking only antigen-activated T cells, while cells effects: (i) the development of anti-xenogeneic antibod-(resting T cells, B cells, monocytes-macrophages) not ies is associated with decreased immunosuppressive involved in the immediate rejection process are not or effects, serum sickness and anaphylactic reactions with minimally affected; moreover, no cytokine-release is repeated administration, (ii) cross-reactions with noninduced, possibly because the a-chain is unable to T cell tissue (e.g. thrombopenia, leukopenia), (iii) morcause signal transduction or internalization. In conbidity due to target cell activating antigen-specific trast, anti-IL-2Rb mAbs are less selective and effective reactions (cytokine release syndrome), and (iv) aspecbut they inhibit IL-2 binding as well as lymphocyte ific over-immunosuppression (e.g. CMV-infection, activation and proliferation [2] . post-transplant lymphoproliferative disorder (PTLD)) due to interference with cells not involved in the rejection process or induction of microbial prolifera-Development of IL-2Ra monoclonal antibodies tion by substances released from anti-T cell antibody activated cells. Recently monoclonal antibodies (mAb) Several murine and rat mAbs to the IL-2Ra (anti-Tac directed against the interleukin-2 receptor (IL-2R) [ The IL-2/IL-2 receptor pathway their widespread clinical use: they have short half-lives in the circulation (<48 h) compared to human IgG Because IL-2-driven T-cell proliferation is a major (21 days), probably due to quick removal induced feature of the acute rejection process, several mAb by naturally occurring anti-rat or anti-mouse (antidirected to the IL-2R have been developed to suppress Gala1-3Gal ) antibodies; they do not effectively recruit the immune response against an allograft. When an immune effector functions; and, sensitization (human appropriately processed and presented antigen inter-anti-mouse [ HAMA] or human anti-rat [HARA] antiacts with the T cell receptor for that specific antigen, bodies), occurring in the majority of treated patients, the resting T cell is activated leading to de novo syn-may decrease their effect with repeated administration. thesis and secretion of IL-2 and to expression of high-In order to circumvent these drawbacks and to reduce affinity IL-2Rs [1] . The IL-2R on resting T cells the number of xenogeneic epitopes, hybridoma technois composed of two polypeptide chains-IL-2Rb logy and recombinant genetic engineering with transfer (CD122) and IL-2Rc (CD132), forming an IL-2Rbc of plasmids containing IgG gene sequences into mouse complex capable of binding IL-2 with intermediate myeloma cells has been applied to produce chimeric affinity. After T cell activation with antigen, the a-and humanized antibodies. Chimeric antibodies consist of the entire variable region of the murine mAb fused Correspondence and offprint requests to: Yves Vanrenterghem, with the human heavy and light chain constant regions; Department of Nephrology, University Hospital Gasthuisberg, humanized antibodies only contain the hypervariable B-3000 Leuven, Belgium. E-mail: Yves.Vanrenterghem@UZ.KULeuven.ac.be.
regions (complementarity-determining or antigen-binding regions) of the parent murine mAb fitted in suggests that besides competitive binding and saturating the CD25 receptor, down-regulation of IL-2R the framework of a human IgG molecule. With these techniques, chimeric and humanized antibodies were expression, shedding of antibody-bound IL-2R or destruction of activated T-cells by ADCC may play a produced without loss of antigen-specificity or significant loss of receptor-affinity but with longer half-role in the mechanism of action. Both agents are easy to administer via peripheral IV infusion during 15 min lifes and without the potential to produce neutralizing antibodies. Moreover, chimeric and humanized anti-in an easy dosing schedule. Because of their pharmacokinetic properties, no adjustments in adults have to be bodies are not only capable of reversible blocking of the IL-2R, but-unlike murine antibodies-also made for weight, age, gender, race or presence of proteinuria [12] [13] [14] . of inducing antibody-dependent cellular cytotoxicity (ADCC ) with human targeted cells; the magnitude of ADCC is isotype-dependent (IgG1>IgG2b>IgG2a).
IL-2Ra monoclonal antibodies: future prospects
Clinical studies with IL-2Ra monoclonal antibodies Despite the promising results obtained with IL-2Ra monoclonal antibodies, some questions have not been Recently, two anti-IL-2Ra mAbs have completed answered at present. phase III trials [7] [8] [9] [10] : (i) basiliximab (SimulectB : t 1/2 : 6.5 days), a chimeric antibody and (ii) daclizumab (i) Although the IL-2/IL-2R pathway is a critical step in the activation of alloreactive T-cells, about 1/3 (ZenapaxB : t 1/2 : 20 days), a humanized anti-Tac antibody. At a dose of 20 mg given prior to transof the acute rejection episodes occur during effective CD25 blockade. This observation reflects the plantation and at day 4, basiliximab maintains CD25 receptor saturation for 30 days. In two placeboredundancy of the rejection cascade. This interpretation is in accordance with the observation controlled phase III trials, basiliximab in combination with steroids and cyclosporin, significantly decreased that IL-2 knockout mice are capable of rejecting a transplanted organ. The ever-present IL-15 may the incidence of acute rejection at 6 months (-26 to −31%) and 12 months (-23 to −29%). Overall graft be a candidate substituting for IL-2 [15]. (ii) Controlled randomized studies with IL-2Ra mAbs and patient survival rates at 12 months however, were similar with basiliximab and placebo. Daclizumab at were performed using conventional immunosuppressive therapy (corticosteroids+cyclosporine a dose of 1 mg/kg given prior to transplantation and every 2 weeks thereafter for a total of five doses, A +/-azathioprine). It is not known whether IL-2Ra mAbs are able to significantly reduce the provided effective CD25 saturation for a period of 90 days. A significant reduction in incidence of acute incidence of acute rejection using double or triple immunosuppressive regimens incorporating newer rejection episodes at 6 months was demonstrated in two placebo-controlled phase III studies, either in small molecular agents, which reduce acute rejection episodes (mycophenolate mofetil, FK-506, combination with steroids and cyclosporin (28 vs 47%) or with steroids, cyclosporin and azathioprine (22 vs rapamycine). (iii) The safety and efficacy of IL-2Ra mAbs raises 35%). Moreover, in combination with triple therapy, 6-month graft survival was significantly better in the questions whether it is possible to reduce other immunosuppressive agents, such as corticosteroids daclizumab group. In the double therapy trial, 6-month patient survival was significantly better in the dacliand calcineurin inhibitors. Two studies are being performed (one using daclizumab, one using zumab group. Whether daclizumab is superior to basiliximab in terms of incidence of acute rejection, basiliximab) to assess safety and efficacy of a steroid-free immunosuppressive regimen; no data graft and patient survival needs to be determined; one might speculate that the slightly better results obtained are available at present. One study is underway to assess safety and efficacy of a daclizumabwith daclizumab in these trials is related to the more prolonged CD25 receptor saturation due to a longer MMF-steroid regimen free of calcineurin inhibitors [16 ] . As expected from initial studies showing half-life and the longer dosing schedule in the daclizumab studies. Basiliximab has the advantage that a synergistic effect of calcineurin inhibitors and IL-2Ra mAbs, a higher incidence of acute rejeconly two doses in the early postoperative days were given.
tions at 3 months (45%) was noted in the latter study. However, approximately 60% of patients Both preparations are safe and well tolerated (no cytokine release syndrome) with comparable incidence did not require institution of calcineurin inhibitors, and therefore may benefit in the long run by and pattern of infections and so far no increase in malignancies compared with the placebo groups. not being exposed to calcineurin inhibitor nephrotoxicity. Anaphylactic or allergic reactions and clinically significant antibody production has not been described (iv) Controlled randomized trials in immunologically high-risk patients (sensitized recipients, regrafts, until now. No significant changes in total T-cells, activated T-cells or T-cell subsets are noticed, apart paediatric patients, simultaneous kidney-pancreas recipients) or patients with delayed graft function from a significant decrease in circulating CD25+ lymphocytes and lymph node lymphocytes [9, 11] ; this are not available. Besides scarce anecdotal reports of safety and efficacy in these patients, only sub-allograft recipients, and long-term efficacy studies are warranted to determine their definitive place in the group analyses from the large phase III trials are available but they are mostly not powered to detect field of immunosuppressive therapy. statistical differences within demographic sub- Transplant Proc 1999; 31: 19S-21S immunosuppressive agents, studies in high-risk renal
